Ledermann JA - Search Results

1

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.

Miller RE, Ledermann JA. Miller RE, et al. Among authors: ledermann ja. Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11. Clin Adv Hematol Oncol. 2016. PMID: 27673289 Review.

2

Targeted trials in ovarian cancer.

Ledermann JA, Raja FA. Ledermann JA, et al. Gynecol Oncol. 2010 Oct;119(1):151-6. doi: 10.1016/j.ygyno.2010.05.008. Epub 2010 Jun 29. Gynecol Oncol. 2010. PMID: 20591473 Review.

3

Primary chemotherapy: the future for the management of advanced ovarian cancer?

Ledermann JA. Ledermann JA. Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S17-9. doi: 10.1111/IGC.0b013e3181f67418. Int J Gynecol Cancer. 2010. PMID: 20975354 Review.

4

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ. Secord AA, et al. Among authors: ledermann ja. Int J Gynecol Cancer. 2013 Jun;23(5):846-52. doi: 10.1097/IGC.0b013e31829527bd. Int J Gynecol Cancer. 2013. PMID: 23666017

5

Ovarian cancer.

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Jayson GC, et al. Among authors: ledermann ja. Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21. Lancet. 2014. PMID: 24767708 Review.

6

Maintenance therapy in ovarian cancer.

Khalique S, Hook JM, Ledermann JA. Khalique S, et al. Among authors: ledermann ja. Curr Opin Oncol. 2014 Sep;26(5):521-8. doi: 10.1097/CCO.0000000000000110. Curr Opin Oncol. 2014. PMID: 25033374 Review.

7

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.

Ledermann JA, El-Khouly F. Ledermann JA, et al. Br J Cancer. 2015 Dec 15;113 Suppl 1(Suppl 1):S10-6. doi: 10.1038/bjc.2015.395. Br J Cancer. 2015. PMID: 26669450 Free PMC article. Review.

8

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA. Matulonis UA, et al. Among authors: ledermann ja. Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8. Cancer. 2016. PMID: 27062051 Free article. Clinical Trial.

9

Homologous recombination deficiency and ovarian cancer.

Ledermann JA, Drew Y, Kristeleit RS. Ledermann JA, et al. Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9. Eur J Cancer. 2016. PMID: 27065456 Review.

10

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.

Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS. Lemech CR, et al. Among authors: ledermann ja. Oncology. 2016;91(1):48-54. doi: 10.1159/000445999. Epub 2016 Jun 3. Oncology. 2016. PMID: 27256106

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

217 results

Search Page